1stOncology™: Cancer Intelligence Service – Page 9930 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Cellectar Granted Japanese Composition of Matter Patent for its Phospholipid-Ether Drug Conjugates

On March 9, 2021 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported that the Japan Patent Office (JPO) has granted patent number 6832861, titled, "Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles (Press release, Cellectar Biosciences, MAR 9, 2021, View Source [SID1234576304])." The patent provides composition of matter and use protection for the company’s proprietary phospholipid-ether (PLE), targeted delivery vehicle analogs in combination with a broad range of commonly used chemotherapeutic classes such as alkaloids, nucleoside analogs, as well as other classes of small molecule chemotherapeutic agents.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"This patent represents an important part of Cellectar’s expanding intellectual property portfolio as the company continues to generate value from R&D and expansion of its PDC franchise," said James Caruso, president and CEO of Cellectar. "Our expanded portfolio now provides intellectual property protection for our small molecule franchise in the major global markets of the U.S., Europe and Japan."

The cancer-targeting PLE delivery vehicle serves as the foundation for the company’s research, development and pipeline including lead product candidate CLR 131, which continues to advance through clinical studies in both adult and pediatric cancer indications.

About Phospholipid Drug Conjugates

Cellectar’s product candidates are built upon a patented delivery platform that utilizes optimized phospholipid ether-drug conjugates (PDCs) to target cancer cells. The PDC platform selectively delivers diverse oncologic payloads to hematologic cancers and solid tumors including cancer stem cells. This selective delivery allows the payloads’ concentration within tumor cells to be increased while reducing the concentration in normal tissue, which may enhance drug potency while reducing adverse events. This platform takes advantage of a metabolic pathway utilized by all tumor cell types. Compared with other targeted delivery platforms, the PDC platform’s mechanism of entry relies on targeting a change in cancer cell membranes that occurs due to the metabolic needs of the cancer which is very different than normal tissue. In addition, PDCs can be conjugated to molecules in numerous ways, thereby increasing the types or classes of molecules that can be selectively delivered. Cellectar believes the PDC platform holds potential for the discovery and development of the next generation of cancer-targeting agents.

Biodesix to Report Fourth Quarter and Fiscal 2020 Financial Results on March 16, 2021

On March 9, 2021 Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, reported that it will release financial results for the fourth quarter and year ended December 31, 2020 after the close of trading on Tuesday, March 16 (Press release, Biodesix, MAR 9, 2021, View Source [SID1234576303]). Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Dial-in and call details are as follows.

Atomwise Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2021

On March 9, 2021 Atomwise, a leader in using artificial intelligence (AI) for small -molecule drug discovery, reported it has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2021 (Press release, Atomwise, MAR 9, 2021, https://www.atomwise.com/2021/03/09/atomwise-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-for-2021/ [SID1234576302]). Atomwise was recognized for its unmatched AI platform, AtomNet️, as well as its growing pipeline and portfolio of partnerships and joint ventures tackling some of the most challenging targets in small molecule drug development.

The list honors businesses that have not only found a way to be resilient in the past year, but also turned those challenges into impact-making processes. These companies did more than survive, they thrived—making an impact on their industries and culture as a whole. This year’s Most Innovative Companies list features 463 businesses from 29 countries.

"The Atomwise team is honored for this recognition from Fast Company," said Dr. Abraham Heifets, PhD, CEO and co-founder of Atomwise. "Achievements like these are a testament to our team’s hard work and dedication to addressing unmet needs for human disease."

Atomwise’s proprietary approach to identifying small molecules for challenging diseases has landed the startup market validation and recognition. With the addition of its robust internal R&D pipeline, the company has made headway to grow its portfolio. Additionally the company has made major traction with corporate partners that include top-tier pharmaceutical companies like Eli Lilly and Bayer, and emerging biotechnology companies in APAC like GC Pharma, Hansoh Pharmaceuticals and Bridge Biotherapeutics. The company recently unveiled its growing portfolio of emerging joint venture companies, with drug development programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders.

The company was also recognized for making notable traction in the area of infectious disease in a very short time. In 2020 the company was awarded a $2.3M grant from the Bill and Melinda Gates Foundation to support the development of multiple global health programs to advance novel antimalarial and anti-tuberculosis small molecule therapies in collaboration with the foundation’s global network. Earlier that same year, Atomwise announced fifteen research collaborations underway with leading global universities to discover novel broad -spectrum antivirals for COVID-19 and other coronaviruses, marking the company’s ability to rapidly spin up multiple programs that tackle different disease mechanisms in parallel. The company also founded a joint venture, vAirus, to develop broad -spectrum antivirals against flaviviruses, a notorious family of viruses that include Zika virus, dengue fever, and West Nile virus.

Fast Company’s editors and writers sought out the most groundbreaking businesses across the globe and industries. They also judged nominations received through their application process.

The World’s Most Innovative Companies is Fast Company’s signature franchise and one of its most highly anticipated editorial efforts of the year. It provides both a snapshot and a road map for the future of innovation across the most dynamic sectors of the economy.

"In a year of unprecedented challenges, the companies on this list exhibit fearlessness, ingenuity, and creativity in the face of crisis," said Fast Company Deputy Editor David Lidsky, who oversaw the issue with Senior Editor Amy Farley.
To coincide with the issue launch, Fast Company will host its first-ever Most Innovative Companies Summit on March 9 and 10. This virtual, multiday summit will celebrate the Most Innovative Companies in business, provide an early look at major business trends, and offer the inspiration and practical insights on what it takes to innovate in 2021. Fast Company’s Most Innovative Companies issue (March/April 2021) is now available online here, as well as in app form via iTunes and on newsstands beginning March 16, 2021. The hashtag is #FCMostInnovative.

Atara Biotherapeutics to Participate in Virtual 33rd Annual ROTH Conference

On March 9, 2021 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, reported that Pascal Touchon, President and Chief Executive Officer, and AJ Joshi, M.D., Chief Medical Officer, will participate in a fireside chat at the Virtual 33rd Annual ROTH Conference on Tuesday, March 16, 2021 at 4:30 p.m. EDT (Press release, Atara Biotherapeutics, MAR 9, 2021, View Source [SID1234576301]).

A live webcast can be accessed by visiting the Investors & Media – News & Events section of atarabio.com. An archived replay will be available on the Company’s website for 30 days following the live webcast.

HOOKIPA Pharma To Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021

On March 9, 2021 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported that it will release fourth quarter and full year 2020 financial results before the market opens on Thursday, March 18, 2021 (Press release, Hookipa Pharma, MAR 9, 2021, View Source [SID1234576297]). Following the release, the Company will host a live conference call and webcast at 8:30 am EDT to discuss its financial results and corporate update.

To access the live conference call, please register here. A live audio webcast of the event will also be available within the Investors & Media section of HOOKIPA’s website at View Source An archived replay will be accessible for 30 days following the event.